NASDAQ$STOK
Stoke Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Stoke Therapeutics reported financial results for the second quarter of 2024 and provided business updates.
Stoke Therapeutics reported revenue of $4.8 million and a net loss of $25.7 million for the second quarter of 2024. The FDA removed the Partial Clinical Hold as the company advances toward a Phase 3 registrational study of zorevunersen.
- FDA removed Partial Clinical Hold on zorevunersen.
- Company plans to share data from Phase 1/2a and OLE studies of zorevunersen at the 15th European Epilepsy Congress in September 2024.
- Company is on track to provide a regulatory update on Phase 3 registrational plans for zorevunersen in the second half of 2024.
- Company is on track to initiate the Phase 1 study (OSPREY) of STK-002 for the treatment of Autosomal Dominant Optic Atrophy (ADOA) this year.
Headline financials
Revenue & EPS history
Stoke Therapeutics · Revenue · Quarterly
$4.83M
Revenue by segment
Stoke Therapeutics · $3.27M total across 1 segment · Q4 2022
- Acadia Pharm.$3.27M—100.0%
Forward guidance
The company plans to share previously presented positive data from patients treated in the Phase 1/2a and open label extension (OLE) studies of zorevunersen in children and adolescents with Dravet syndrome at the 15th European Epilepsy Congress (EEC), September 7 – 11, 2024, in Rome, Italy. The company is on track to initiate the Phase 1 study (OSPREY) of STK-002 for the treatment of Autosomal Dominant Optic Atrophy (ADOA) this year.
Tailwinds
- Company plans to share data from Phase 1/2a and OLE studies of zorevunersen at the 15th European Epilepsy Congress in September 2024.
- Company is on track to provide a regulatory update on Phase 3 registrational plans for zorevunersen in the second half of 2024.
- Company is on track to initiate the Phase 1 study (OSPREY) of STK-002 for the treatment of Autosomal Dominant Optic Atrophy (ADOA) this year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+4.2%
Avg return
Earnings day
+4.9%
Avg return
5 days after
+3.1%
Avg return
30 days after
48%
13 / 27 earnings
Positive
+63.3%
Q4 2023
Best reaction
-20.0%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.5% | -2.6% | -9.8% | |
| Q4 2025 | -2.8% | -1.3% | +4.1% | |
| Q3 2025 | -10.1% | -11.7% | +21.8% | |
| Q1 2025 | +1.2% | -1.6% | +19.7% | |
| Q4 2024 | -1.4% | -9.4% | -14.6% | |
| Q3 2024 | +1.1% | +6.0% | -4.0% | |
| Q2 2024 | -0.6% | +1.5% | +3.3% | |
| Q1 2024 | -0.7% | -4.5% | +36.5% | |
| Q4 2023 | +63.3% | +114.3% | +85.1% | |
| Q3 2023 | +7.0% | -1.2% | +6.7% | |
| Q2 2023 | -9.3% | -11.1% | -13.4% | |
| Q1 2023 | +25.9% | +28.1% | +28.2% | |
| Q4 2022 | +4.5% | -1.0% | -10.1% | |
| Q3 2022 | -20.0% | -35.9% | -32.9% | |
| Q2 2022 | +31.7% | +28.6% | -10.8% | |
| Q1 2022 | +2.0% | +17.3% | +0.6% | |
| Q4 2021 | -1.6% | -2.1% | +9.8% | |
| Q3 2021 | +3.0% | +9.4% | -20.2% | |
| Q2 2021 | -1.4% | -2.4% | -1.6% | |
| Q1 2021 | +11.3% | +9.9% | +26.6% | |
| Q4 2020 | +6.8% | +1.5% | -30.2% | |
| Q3 2020 | -0.5% | -7.8% | +14.6% | |
| Q2 2020 | +4.7% | +8.5% | +18.6% | |
| Q1 2020 | +15.3% | +18.9% | -6.0% | |
| Q4 2019 | -3.9% | -2.3% | -6.5% | |
| Q3 2019 | -11.1% | -21.7% | -20.0% | |
| Q2 2019 | +0.0% | +5.3% | -11.4% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro